10:35 AM EDT, 06/30/2025 (MT Newswires) -- Moderna ( MRNA ) said Monday that late-stage trial data showed its experimental flu vaccine was more effective than currently available shots.

The mRNA-1010 product demonstrated efficacy of 26.6% in adults aged 50 years and above, higher than a licensed influenza vaccine, according to the drugmaker. The experimental drug showed "strong" relative efficacy for each influenza strain contained in the vaccine.

Patients aged 65 and above demonstrated a relative vaccine efficacy of 27.4%, Moderna ( MRNA ) said.

Shares of the company rose 2.4% in Monday trade. The stock is down 33% so far this year.

"Today's strong phase 3 efficacy results are a significant milestone in our effort to reduce the burden of influenza in older adults," Moderna ( MRNA ) Chief Executive Stephane Bancel said in a statement. "An mRNA-based flu vaccine has the potential advantage to more precisely match circulating strains, support rapid response in a future influenza pandemic, and pave the way for COVID-19 combination vaccines."

The mRNA-1010 candidate's safety and tolerability were consistent with results from a previous phase 3 study, the company said. The drugmaker plans to present the latest data at an upcoming medical conference and discuss the product's filing submissions with relevant regulators.

Moderna ( MRNA ) in May withdrew a biologics license application for its combination shot targeting COVID-19 and influenza, saying it would resubmit it with efficacy data from mRNA-1010's phase 3 trial.

Earlier in June, Moderna ( MRNA ) said the US Food and Drug Administration approved its mRESVIA vaccine to prevent lower respiratory tract disease caused by respiratory syncytial virus. At the end of last month, the FDA approved the company's mNEXSPIKE COVID-19 vaccine for people aged 65 years and above.

Price: 27.73, Change: +0.57, Percent Change: +2.10